AD-A106 055 LETTERMAN ARMY INST OF RESEARCH PRESIDIO OF SAN FRANC--ETC F/G 6/20
THE MUTAGENIC POTENTIAL OF: 4-FLUOROPHENYL METHYL (PHENYL) PHOS--ETC(U)
SEP 81 L J SAUERS, F R PULLIAM, J T FRUIN
UNCLASSIFIED LAIR-106 NL



LEVEL II

INSTITUTE REPORT NO. 106

THE MUTAGENIC POTENTIAL OF:

4-fluorophenyl methyl (phenyl) phosphinate,
4-nitrophenyl 4-trifluoromethylphenyl (methyl) phosphinate,
4-nitrophenyl 3-trifluoromethylphenyl (methyl) phosphinate,
4-methylsulfinylphenyl methyl (phenyl) phosphinate.

LEONARD J. SAUERS, BA, SP5
FREDDICA R. PULLIAM, BS, SSG
and
JOHN T. FRUIN, DVM, PhD, LTC VC

TOXICOLOGY GROUP,
DIVISION OF RESEARCH SUPPORT

SEP 1981

Toxicology Series - 19

LETTERMAN ARMY INSTITUTE OF RESEARCH PRESIDIO OF SAN FRANCISCO CALIFORNIA 94129

Toxicology Series 19

This material has been reviewed by Letterman Army Institute of Research and there is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense. *(AR 360-5)*



(Signature and date)

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE *(When Data Entered)*

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER LAIR Institute Report No. 106	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE *(and Subtitle)* The Mutagenic Potential of 4 fluorophenyl methyl(phenyl)phosphinate; 4-nitrophenyl 4-trifluoromethylphenyl(methyl)phosphinate; 4-nitrophenyl 3-trifluoromethylphenyl(methyl)phosphinate; 4-methylsulfinylphenyl methyl(phenyl)phosphinate.		5. TYPE OF REPORT & PERIOD COVERED Final June 1981 - September 1981
		6. PERFORMING ORG. REPORT NUMBER
7. AUTHOR(s) Leonard J. Sauers, BA, SP5; Freddica R. Pulliam, BS, SSG; John T. Fruin, DVM, PhD, LTC VC;		8. CONTRACT OR GRANT NUMBER(s)
9. PERFORMING ORGANIZATION NAME AND ADDRESS Toxicology Group, Div. of Research Support Letterman Army Institute of Research Presidio of San Francisco, CA 94129		10. PROGRAM ELEMENT PROJECT, TASK AREA & WORK UNIT NUMBERS 2 Project 3516772A875 WU 304
11. CONTROLLING OFFICE NAME AND ADDRESS U.S. Army Medical Research and Development Command Fort Detrick Frederick, MD 21701		12. REPORT DATE September 1981
		13. NUMBER OF PAGES 38
14. MONITORING AGENCY NAME & ADDRESS *(if different from Controlling Office)*		15. SECURITY CLASS. *(of this report)* UNCLASSIFIED
		15a. DECLASSIFICATION DOWNGRADING SCHEDULE

16. DISTRIBUTION STATEMENT *(of this Report)*

APPROVED FOR PUBLIC RELEASE: DISTRIBUTION UNLIMITED.

17. DISTRIBUTION STATEMENT *(of the abstract entered in Block 20, if different from Report)*

18. SUPPLEMENTARY NOTES

19. KEY WORDS *(Continue on reverse side if necessary and identify by block number)*

Mutagenicity; Toxicology, Ames Assay; 4 fluorophenyl methyl(phenyl)phosphinate; 4-nitrophenyl 4-trifluoromethylphenyl(methyl)phosphinate; 4-nitrophenyl 3-trifluoromethyl phenyl(methyl)phosphinate; 4-methylsulfinylphenyl methyl(phenyl) phosphinate.

20. ABSTRACT *(Continue on reverse side if necessary and identify by block number)*

The mutagenic potential of 4 fluorophenyl methyl(phenyl)phosphinate (44*); 4-nitrophenyl 4-trifluoromethylphenyl(methyl)phosphinate (86*); 4-nitrophenyl 3-trifluoromethylphenyl(methyl)phosphinate (4*); 4-methylsulfinylphenyl methyl(phenyl)phosphinate (96*) was assessed by using the Ames Salmonella/Mammalian Microsome Mutagenicity Assay. Tester strains TA 98, TA 100, TA 1535, TA 1537 and TA 1538 were exposed to doses ranging from 1 mg/plate to 3.2×10^{-4} mg/plate. It was determined that none of the tested substances had mutagenic potential.
* Code number for compound.

DD FORM 1 JAN 73 1473 EDITION OF 1 NOV 65 IS OBSOLETE

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE *(When Data Entered)*

ABSTRACT

The mutagenic potential of 4 fluorophenyl methyl(phenyl)phosphinate (44*); 4-nitrophenyl 4-trifluoromethylphenyl(methyl)phosphinate (86*); 4-nitrophenyl 3-trifluoromethylphenyl(methyl)phosphinate (4*); 4-methylsulfinylphenyl methyl(phenyl)phosphinate (96*) was assessed by using the Ames Salmonella/Mammalian Microsome Mutagenicity Assay. Tester strains TA 98, TA 100, TA 1535, TA 1537, and TA 1538 were exposed to doses ranging from 1 mg/plate to 3.2 x 10-4 mg/plate. It was determined that none of the tested substances had mutagenic potential.

* Code number for compound.

PREFACE

AMES ASSAY REPORT:

SUBSTANCE	CODE NO.
4 fluorophenyl methyl(phenyl)phosphinate	44
4-nitrophenyl trifluoromethylphenyl(methyl)phosphinate	86
4-nitrophenyl 3-trifluoromethylphenyl(methyl)phosphinate	4
4-methylsulfinylphenyl methyl(phenyl)phosphinate	96

TESTING FACILITY: Letterman Army Institute of Research
Presidio of San Francisco, CA 94129

SPONSOR: Biomedical Laboratory, Aberdeen Proving Grounds
Aberdeen, MD 21005

PROJECT: Toxicity Testing of Phosphinate Compounds - 35162772A875

GLP STUDY NUMBER: 81014

STUDY DIRECTOR: LTC John T. Fruin, D.V.M.,PhD.
CO-PRINCIPAL INVESTIGATORS: SSG Freddica R. Pulliam, B.S.
SP5 Leonard J. Sauers, B.A.

RAW DATA: A copy of the final report, study protocol and retired SOPs will be maintained in the LAIR archives. Test substances were provided by sponsor. Chemical, analytical, stability, purity, etc. data are available from the sponsor.

PURPOSE: To determine the mutagenic potential of the above compounds using the Ames Assay. Tester strains TA 98, TA 100, TA 1535, TA 1537, and TA 1538 were used.

ACKNOWLEDGMENTS

The authors wish to thank John Dacey and SP4 Larry Mullen, BS for their assistance in performing the research and for help in preparation of this report.

Signatures of Principal Scientists
Involved in the Study

We, the undersigned, believe the study, GLP number 81014, described in this report to be scientifically sound and the results and interpretation to be valid. The study was conducted to comply to the best of our ability with the Good Laboratory Practice Regulations outlined by the Food and Drug Administration.

FREDDICA R. PULLIAM, BS Date
SSG
Co-Investigator

JOHN T. FRUIN, DVM, PhD Date
LTC, VC
Study Director

LEONARD J. SAUERS, BA Date
SP5
Co-Investigator

DEPARTMENT OF THE ARMY
LETTERMAN ARMY INSTITUTE OF RESEARCH
PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129

REPLY TO
ATTENTION OF:

SGRD-ULZ-QA

22 July 1981

MEMORANDUM FOR RECORD

SUBJECT: Report of GLP Compliance

I hereby certify that in relation to LAIR GLP study 81014 the following inspections were made:

5 June 1981
12 June 1981

Routine inspections with no adverse findings are reported quarterly, thus these inspections are also included in the July 1981 report to management.

JOHN C. JOHNSON
CPT, MS
Quality Assurance Officer

TABLE OF CONTENTS

Rationale for using the Ames Assay

The Ames Salmonella/Mammalian Microsome Mutagenicity Test is one of a standard bank of tests used by our laboratory for the assessment of the mutagenic potential of a test substance. It is a short-term screening assay for the prediction of potential mutagenic agents in mammals. It is inexpensive when compared to *in vivo* tests, yet is highly predictive and reliable in its ability to detect mutagenic activity and therefore carcinogenic probability (1). It relies on basic genetic principles and allows for the incorporation of a mammalian microsome enzyme system to increase sensitivity through enzymatically altering the test substance into an active metabolite. It has proven highly effective in assessing human risk (1).

Description of Test (Rationale for the selection of strains)

The test was developed by Bruce Ames, Ph.D. from the University of California-Berkeley. The test involves the use of several different genetically altered strains of *Salmonella typhimurium*, each with a specific mutation in the histidine operon (2). The test substance demonstrates mutagenic potential if it is able to revert the mutation in the bacterial histidine operon back to the wild type and thus reestablish prototrophic growth within the test strain. This reversion also can occur spontaneously due to a random mutational event. If, after adding a test substance, the number of revertants is significantly greater than the spontaneous reversion rate, then the test substance physically altered the locus involved in the operon's mutation and is able to induce point mutations and genetic damage (2).

In order to increase the sensitivity of the test system, two other mutations in the Salmonella are used (2). To insure a higher probability of uptake of test substance, the genome for the lipopolysacchride layer (LP) is mutated and allows larger molecules to enter the bacteria. Each strain has another induced mutation which causes loss of excision repair mechanisms. Since many chemicals are not by themselves mutagenic but have to be activated by an enzymatic process, a mammalian microsome system is incorporated. These microsomal enzymes are obtained from livers of rats induced with Aroclor 1254; the enzymes allow for the expression of the metabolites in the mammalian system. This activated rat liver microsomal enzyme homogenate is termed S-9.

Description of Strains (History of the strains used, methods to monitor the integrity of the organisms, and data pertaining to current and historical controls and spontaneous reversion rates)

The test consists of using five different strains of Salmonella typhimurium that are unable to grow in absence of histidine because of a specific mutation in the histidine operon. This histidine requirement is verified by attempting to grow the tester strains on minimal glucose agar (MGA) plates, both with and without histidine. The dependence on this amino acid is shown when growth occurs only in its presence. The plasmids in strains TA 98 and TA 100 contain an ampicillin resistant R factor. Strains deficient in this plasmid demonstrate a zone of growth inhibition around an ampicillin impregnated disc. The alteration of the LP layer allows uptake by the Salmonella of larger molecules. If a crystal violet impregnated disc is placed onto a plate containing any one of the bacterial strains, a zone of growth inhibition will occur because the LP layer is altered. The absence of excision repair mechanisms can be determined by using ultraviolet (UV) light. These mechanisms function primarily by repairing photodimers between pyrimidine bases; exposure of bacteria to UV light will activate the formation of these dimers and cause cell lethality, since excision of these photodimers can not be made. The genetic mutation resulting in UV sensitivity also induces a dependence by the Salmonella to biotin. Therefore, this vitamin must be added. In order to prove that the bacteria are responsive to the mutation process, positive controls are run with known mutagens. If after exposure to the positive control substance, a larger number of revertants are obtained, then the bacteria are adequately responsive. Sterility controls are performed to determine the presence of contamination. Sterility of the test compound is also confirmed in each first dilution. Verification of the tester strains occurs spontaneously with the running of each assay. The value of the spontaneous reversion rate is obtained using the same inoculum of bacteria that is used in the assay (3).

Strains were obtained directly from Dr. Ames, University of California, Berkeley, propagated and then maintained at -80 C in our laboratory. Before any substance was tested, quality controls were run on the bacterial strains to establish the validity of their special features and also to determine the spontaneous reversion rate (2). Records are maintained of all the data, to determine if deviations from the set trends have occurred.

We compared the spontaneous reversion values with our own historical values and those cited by Ames et al (2). Our conclusions are based on the spontaneous reversion rate compared to the experimentally induced rate of mutation. When operating effectively, these strains detect substances that cause base pair

mutations (TA 1535, TA 100) and frameshift mutations (TA 1537, TA 1538 and TA 98) (2).

METHODS (3)

Rationale for Dosage Levels and Dose Response Tabulations

To insure readable and reliable results, a sublethal concentration of the test substance had to be determined. This toxicity level was found by using MGA plates, various concentrations of the substance, and approximately 10^8 cells of TA 100 per plate, unless otherwise specified. Top agar containing trace amounts of histidine and biotin were placed on MGA plates. TA 100 is used because it is the most sensitive strain. Strain verification was confirmed on the bacteria, along with a determination of the spontaneous reversion rate. After incubation, the growth was observed on the plates. (The auxotrophic Salmonella will replicate a few times and potentially express a mutation. When the histidine and biotin supplies are exhausted, only those bacteria that reverted to the prototrophic phenotype will continue to reproduce and form macrocolonies; the remainder of the bacteria comprises the background lawn. The minimum toxic level is defined as the lowest serial dilution at which decreased macrocolony formation, below that of the spontaneous revertant rate, and an observable reduction in the density of the background lawn occurs.) A maximum dose of 1 mg/plate is used when no toxicity is observed. The densities were recorded as normal slight, and no growth.

Test Format

After we validated our bacterial strains and determined the optimal dosage of the test substance, we began the Ames Assay. In the actual experiment, 0.1ml of the particular strain of Salmonella (10^8 cells) and the specific dilutions of the test substance were added to 2 ml of molten top agar, which contained trace amounts of histidine and biotin. Since survival is better from cultures which have just passed the log phase, the Salmonella strains were used 16 hours (maximum) after initial inoculation into nutrient broth. The dose of the test substance spanned more than a 1000- fold, decreasing from the minimum toxic level by a dilution factor of 5. All the substances were tested with and without S-9 microsome fraction. The S-9 mixture which was previously titered at an optimal strength was added to the molten top agar. After all the ingredients were added, the top agar was vortexed, then overlayered on minimum glucose agar plates. These plates contained 2% glucose and Vogel Bonner "E" Concentrate (4). The water used in this medium and all reagents came from a polymetric system. Plates were incubated, upside down in the dark at 37 C for 48 hours. Plates were prepared in triplicate and

the average revertant counts were recorded. The corresponding number of revertants obtained was compared to the number of spontaneous revertants; the conclusions were recorded statistically. A correlated dose response is considered necessary to declare a substance as a mutagen. Commoner (5), in his report, "Reliablilty of Bacterial Mutagenesis Techniques to Distinguish Carcinogenic and Non-Carcinogenic Chemical," and McCann et al (1) in their paper, "Detection of Carcinogens as Mutagen: Assay of over 300 Chemicals," have concurred on the test's ability to detect mutagenic potential.

Statistical Analysis

Quantitative evaluation was ascertained by two independent methods. Ames et al (2) assumed that a compound which caused twice the spontaneous reversion rate is mutagenic. Commoner (5), developed the MUTAR Ratio, which is stated in the following equation:

$$MUTAR = (E - C)/C_{AV}$$

Here, C is the number of spontaneous revertant colonies on control plates obtained on the same day and with the same treatment and strains. E is the number of revertants in response to the compound; C_{AV} is the number of spontaneous revertants on control plates calculated from historical records. The explanation of the results of this equation can be determined by the method of Commoner (5). This variation determines the probability of correctly classifying substances as carcinogens on the basis of their mutagenic activity. The E values were recorded by strain, with and without S-9. Values for C and C_{AV} were recorded separately.

We used the formula and logged all values for our permanent records.

RESULTS AND DISCUSSION

Throughout this report, each of the test substances will be referred to by the respective code number:

Substance	Code No.
4 fluorophenyl methyl(phenyl)phosphinate	44
4-nitrophenyl 4-trifluoromethylphenyl(methyl)phosphinate	86
4-nitrophenyl 3-trifluoromethylphenyl(methyl)phosphinate	4
4-methylsulfinylphenyl methyl(phenyl)phosphinate	96

On 5 June 1981, the Toxicity Level Determination was performed on the 4 test chemicals. All sterility, positive, and negative controls for this experiment were normal (Table 1). At the highest dose used, 1.0 mg/plate, no toxicity was observed (Tables 2A-2D).

On 12 June 1981, the Ames Assay was performed using the 4 test substances. For this experiment, all sterility and strain verification controls were normal (Table 3). Expected responses were observed for all negative and positive controls except for the response of TA 1537 and TA 1538 to dimethyl benzanthracene (DMBA) (Table 4).

For all chemicals tested, no evidence of mutagenic potential was observed (Tables 5A-5D).

The MUTAR values listed in Tables 6A-6D, were within the normal limits.

CONCLUSION

By the Ames Assay, test compounds, 86, 44, 4 and 96 are not mutagenic at the levels tested.

RECOMMENDATION

We recommend that organophosphinate compounds 86, 44, 4 and 96 be tested by using other toxicological testing systems if efficacy tests show these chemicals to be promising antidotes.

REFERENCES

1. McCANN, J., E. CHOI, E. YAMASAKI, and B. N. AMES. Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals. Proc Nat Acad Sci, USA 72:5135-5139, 1975

2. AMES, B. N., J. McCANN and E. YAMASAKI. Methods for detection carcinogens and mutagens with Salmonella/mammalian microsome mutagenicity test. Mutation Res 31: 347-364, 1975

3. LAIR SOP OP-STX-1, Ames Salmonella/mammalian microsome mutagenicity test, 1 March 1981

4. VOGEL, H. J. and D. M. BONNER. Acetylornithinase of E. coli: Partial purification and same properties. J Biol Chem 218: 97-106, 1956

5. COMMONER, B. Reliability of the bacterial mutagenesis techniques to distinguish carcinogenic and non-carcinogenic chemicals. EPA 600/1 76-022, 1976

LIST OF TABLES

APPENDIX

TABLE 1

STRAIN VERIFICATION FOR TOXICITY LEVEL DETERMINATION
Salmonella/Microsome Assay

Strain No.	Histidine Requirements	Ampicillin Resistance	uvr-B Deletion	rfa Crystal Violet	Sterility Control	Response (a)
TA 100	NG	G	NG	14.15 mm	NG	+
TA 1537	NA	NG	NA	NA	NG	+
WT	G	NA	G	NA	NA	+
Diluent	NA	NA	NA	NA	NG	+
Positive Control - MNNG - Test Compound (s)		Average - 1612				
(a) 44	NA	NA	NA	NA	NG	+
(b) 86	NA	NA	NA	NA	NG	+
(c) 4	NA	NA	NA	NA	NG	+
(d) 96	NA	NA	NA	NA	NG	+
(e) NA	NA	NA	NA	NA	NA	NA

G = Growth; NG = No Growth; NT = Not Tested; NA = Not Applicable;
WT = Wild Type; (a) + = Expected Response; - = Unexpected Response

Spontaneous Revertants

Strain	Time				Average
TA 100	Beginning	152	116	139	
TA 100	End	159	157	142	144

Test Inculated By: Sauers, Pulliam, Dacey, Mullen Date 3 June 1981

Test Read By: Sauers, Pulliam Date 5 June 1981

TABLE 2A

TOXICITY LEVEL DETERMINATION
Salmonella/Microsome Assay

Substance assayed: (1) Code #86 (2) _____ _____

(3) _____ (4) _____ (5) _____

Date: 3 June 1981 Performed by: Sauers, Pulliam, Dacey, Mullen

Substance dissolved in: (1) DMSO (2) _____ (3) _____

(4) _____ (5) _____

Visual estimation of background lawn on
Nutrient Agar Plates: NG = no growth
ST = slight growth
NL = normal growth

TA 100
Revertant Plate Count

Test Compound Concentration	Plate #1	Plate #2	Plate #3	Average	Background Lawn
1 mg/plate	140	118	111	125	NL
10^{-1} mg/plate	147	182	164	164	NL
10^{-2} mg/plate	151	167	170	163	NL
10^{-3} mg/plate	155	171	145	157	NL
10^{-4} mg/plate	121	99	NG	110	NL
10^{-5} mg/plate	167	153	120	147	NL
10^{-6} mg/plate	143	134	159	145	NL
10^{-7} mg/plate	152	171	189	171	NL

TABLE 2B

TOXICITY LEVEL DETERMINATION
Salmonella/Microsome Assay

Substance assayed: (1) Code #44 (2) _____

(3) _____ (4) _____ (5) _____

Date: 3 June 1981 Performed by: Sauers, Pulliam, Dacey, Mullen

Substance dissolved in: (1) DMSO (2) _____ (3) _____

(4) _____ (5) _____

Visual estimation of background lawn on Nutrient Agar Plates: NG = no growth
ST = slight growth
NL = normal growth

TA 100
Revertant Plate Count

Test Compound Concentration	Plate #1	Plate #2	Plate #3	Average	Background Lawn
1 mg/plate	127	167	148	147	NL
10^{-1} mg/plate	160	149	133	147	NL
10^{-2} mg/plate	132	131	162	142	NL
10^{-3} mg/plate	156	139	151	149	NL
10^{-4} mg/plate	99	108	151	119	NL
10^{-5} mg/plate	165	171	159	165	NL
10^{-6} mg/plate	145	145	143	144	NL
10^{-7} mg/plate	165	167	198	177	NL

TABLE 2C

TOXICITY LEVEL DETERMINATION
Salmonella/Microsome Assay

Substance assayed: (1) Code #4 (2) _____

(3) _____ (4) _____ (5) _____

Date: 3 June 1981 Performed by: Sauers, Pulliam, Dacey, Mullen

Substance dissolved in: (1) DMSO (2) _____ (3) _____

(4) _____ (5) _____

Visual estimation of background lawn on Nutrient Agar Plates: NG = no growth
ST = slight growth
NL = normal growth

TA 100
Revertant Plate Count

Test Compound Concentration	Plate #1	Plate #2	Plate #3	Average	Background Lawn
1 mg/plate	102	112	113	109	NL
10^{-1} mg/plate	113	92	130	112	NL
10^{-2} mg/plate	138	122	126	129	NL
10^{-3} mg/plate	116	152	158	142	NL
10^{-4} mg/plate	128	160	119	136	NL
10^{-5} mg/plate	150	159	134	148	NL
10^{-6} mg/plate	150	165	155	157	NL
10^{-7} mg/plate	189	170	127	162	NL

TABLE 2D

TOXICITY LEVEL DETERMINATION
Salmonella/Microsome Assay

Substance assayed: (1) Code #96 (2) _____

(3) _____ (4) _____ (5) _____

Date: 3 June 1981 Performed by: Sauers, Pulliam, Dacey, Mullen

Substance dissolved in: (1) DMSO (2) _____ (3) _____

(4) _____ (5) _____

Visual estimation of background lawn on Nutrient Agar Plates: NG = no growth
ST = slight growth
NL = normal growth

TA 100
Revertant Plate Count

Test Compound Concentration	Plate #1	Plate #2	Plate #3	Average	Background Lawn
1 mg/plate	149	148	153	150	NL
10^{-1} mg/plate	135	182	124	147	NL
10^{-2} mg/plate	163	142	168	158	NL
10^{-3} mg/plate	153	182	152	162	NL
10^{-4} mg/plate	94	96	90	93	NL
10^{-5} mg/plate	95	102	140	112	NL
10^{-6} mg/plate	129	119	134	127	NL
10^{-7} mg/plate	144	136	136	139	NL

TABLE 3

STRAIN VERIFICATION CONTROL

Strains	Histidine Requirement	Ampicillin Resistance	UV	Sensitivity to Crystal Violet	Sterility Control	Response (1)
98	NG	G	NG	16.15 mm	NG	+
100	NG	G	NG	17.26 mm	NG	+
1535	NG	NA	NG	14.11 mm	NG	+
1537	NG	21.26 mm	NG	15.34 mm	NG	+
1538	NG	NA	NG	15.39 mm	NG	+
WT	G	NA	G	NA	NA	+

STERILITY CONTROL

His-Bio Mix Initial: NG End: NG Diluent: NG

Top Agar Initial: NG End: NG MGA Plate: NG

S-9 Mix Initial: NG End: NG Nutrient Broth: NG

Test Compound (a) 96-NG (b) 4-NG (c) 44-NG (d) 86-NG (e) NA (f) NA

G = Growth NG = No Growth NT = Not Tested NA = Not Applicable WT = Wild Type

Study Number: 81014 By: Sauers, Pulliam.

Date: 12 June 1981 Dacey, Mullen

(1) + = expected response

- = unexpected response

TABLE 4

SPONTANEOUS REVERTANT RATE AND POSITIVE CONTROL REVERTANT RATE

Compd.	Amount of Compd. Added	S-9 Added	Strain Number 98	100	1535	1537	1538
AF	2 ug/plate	yes	(329,558,235) (374)	(369,168,315) (284)			(256,580,487) (441)
BF	2 ug/plate	yes	(62,66,59) (62)	(234,302,396) (311)		(12,69,52) (44)	(97,115,72) (95)
DMBA	20 ug/plate	yes	(62,71,66) (66)	(251,202,264) (239)		(16,15,15) (15)	(38,41,18) (32)
MNNG	2 ug/plate	no		(912,1154,760) (942)			
	20 ug/plate	no			(112,216,366) (231)		

Strain Performance

Spontaneous Revertants	S-9 Added	98	100	1535	1537	1538
before	yes	(37,19,19)	(89,80,123)	(14,8,9)	(5,7,7)	(15,12,9)
after		(37,37,28) (30)	(141,135,118) (114)	(7,9,12) (10)	(12,10,6) (8)	(26,23,29) (19)
before	no	(26,15,19)	(80,87,93)	(25,12,11)	(9,7,6)	(5,18,17)
after		(20,26,24) (22)	(102,99,106) (94)	(17,20,17) (17)	(7,4,8) (7)	(21,26,22) (18)

Study Number: 81014

Date: 12 Jun 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 5A

NUMBER OF REVERTANTS/PLATE

Compd.	Amount of Compd. Added	S-9 Added	Strain Number 98	100	1535	1537	1538
Code #36	1 mg/plate	no	(10,17,15) (14)	(95,83,108) (95)	(15,13,15) (14)	(8,4,5) (6)	(9,13,12) (11)
		yes	(20,35,24) (26)	(126,98,112) (112)	(9,4,5) (6)	(8,8,4) (7)	(21,14,23) (19)
Code #86	0.2 mg/plate	no	(14,18,20) (17)	(102,97,80) (93)	(20,19,12) (17)	(5,4,6) (5)	(4,10,7) (7)
		yes	(19,26,29) (25)	(110,93,102) (102)	(8,10,9) (9)	(6,5,9) (7)	(31,27,30) (29)
Code #86	0.04 mg/plate	no	(17,12,12) (14)	(75,90,107) (91)	(7,19,11) (12)	(7,2,7) (5)	(11,12,11) (11)
		yes	(35,30,30) (32)	(137,120,104) (120)	(9,10,12) (10)	(8,10,6) (8)	(32,22,37) (30)

-continued

Study Number: 81014 Date: 19 Jun 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 5A, concluded

NUMBER OF REVERTANTS/PLATE

Compd.	Amount of Compd. Added	S-9 Added	Strain Number 98	100	1535	1537	1538
Code #86	0.008 mg/plate	no	(17,19,14) (17)	(94,30,113) (96)	(17,7,10) (11)	(7,10,8) (8)	(14,17,7) (13)
		yes	(29,23,35) (29)	(116,140,93) (116)	(10,9,10) (10)	(9,7,4) (7)	(28,30,24) (27)
Code #86	0.0016 mg/plate	no	(15,18,15) (16)	(95,104,107) (102)	(10,14,12) (12)	(11,10,6) (9)	(5,10,14) (10)
		yes	(26,18,27) (24)	(136,116,117) (123)	(14,12,20) (15)	(12,10,12) (11)	(12,18,36) (22)
Code #86	0.00032 mg/plate	no	(12,19,12) (14)	(95,108,113) (105)	(19,18,15) (17)	(6,5,8) (6)	(18,10,13) (14)
		yes	(24,32,28) (28)	(128,120,92) (113)	(11,11,15) (12)	(7,5,6) (6)	(23,17,26) (22)

Study Number: 81014 Date: 19 Jun 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 5B

NUMBER OF REVERTANTS/PLATE

Compd.	Amount of Compd. Added	S-9 Added	Strain Number 98	100	1535	1537	1538
Code #44	1 mg/plate	no	(15,23,15) (13)	(70,53,54) (59)	(3,5,4) (4)	(2,2,3) (2)	(8,7,7) (7)
		yes	(40,17,23) (27)	(85,80,80) (82)	(10,6,5) (7)	(12,8,4) (8)	(4,5,3) (4)
Code #44	0.2 mg/plate	no	(31,16,12) (20)	(83,102,91) (92)	(20,15,14) (16)	(5,3,8) (5)	(13,12,4) (10)
		yes	(29,25,32) (29)	(121,111,113) (115)	(6,9,9) (8)	(10,9,4) (8)	(22,21,22) (22)
Code #44	0.04	no	(25,14,20) (20)	(92,95,69) (85)	(18,19,20) (19)	(4,7,3) (5)	(12,11,12) (12)
		yes	(21,21,30) (24)	(108,117,97) (107)	(12,8,12) (11)	(4,6,5) (5)	(7,25,29) (20)

- continued

Study Number: 81014 Date: 19 Jun 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 5B, concluded

NUMBER OF REVERTANTS/PLATE

Compd.	Amount of Compd. Added	S-9 Added	Strain Number 98	100	1535	1537	1538
Code #44	0.008 mg/plate	no	(18,20,23) (20)	(72,100,96) (89)	(15,23,20) (19)	(7,6,6) (6)	(12,9,9) (10)
		yes	(26,34,24) (28)	(133,112,109) (118)	(11,14,11) (12)	(5,8,7) (7)	(27,17,15) (20)
Code #44	0.0016 mg/plate	no	(13,26,12) (17)	(93,86,70) (83)	(11,10,8) (10)	(5,3,6) (5)	(6,12,14) (11)
		yes	(23,29,21) (24)	(95,103,99) (99)	(12,13,8) (11)	(5,15,5) (8)	(32,17,20) (23)
Code #44	0.00032 mg/plate	no	(29,11,13) (18)	(98,96,105) (100)	(15,17,15) (16)	(2,6,3) (4)	(7,10,12) (10)
		yes	(31,26,24) (27)	(119,103,103) (108)	(20,13,11) (15)	(6,4,11) (7)	(12,28,15) (18)

Study Number: 81014 Date: 19 June 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 5C

NUMBER OF REVERTANTS/PLATE

Compd.	Amount of Compd. Added	S-9 Added	Strain Number 98	100	1535	1537	1538
Code #4	1 mg/plate	yes	(21,17,22) (20)	(127,164,133) (141)	(9,8,7) (8)	(9,8,7) (8)	(13,17,28) (19)
		no	(13,15,15) (14)	(125,127,92) (115)	(20,14,15) (16)	(4,9,6) (6)	(18,16,19) (18)
Code #4	0.2 mg/plate	yes	(17,32,23) (24)	(115,113,110) (113)	(9,17,9) (12)	(5,9,8) (7)	(18,15,12) (15)
		no	(17,17,12) (15)	(74,72,82) (76)	(15,18,18) (17)	(10,3,8) (7)	(10,6,7) (8)
Code #4	0.04 mg/plate	yes	(25,23,28) (25)	(140,104,116) (120)	(9,13,12) (11)	(7,7,5) (6)	(12,19,16) (16)
		no	(17,20,12) (16)	(75,85,90) (83)	(12,8,14) (11)	(4,6,8) (6)	(8,9,14) (10)

-continued

Study Number: 81014 Date: 19 June 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 5C, concluded

NUMBER OF REVERTANTS/PLATE

Compd.	Amount of Compd. Added	S-9 Added	Strain Number 98	100	1535	1537	1538
Code #4	0.008 mg/plate	no	(18,15,17) (16)	(63,77,107) (82)	(20,31,14) (22)	(10,9,6) (8)	(24,17,36) (26)
		yes	(27,28,23) (26)	(139,148,129) (139)	(8,8,12) (9)	(6,5,9) (7)	(26,15,38) (26)
Code #4	0.0016 mg/plate	no	(16,16,21) (18)	(95,105,96) (99)	(17,15,18) (17)	(6,6,4) (5)	(19,7,17) (14)
		yes	(39,40,28) (36)	(160,154,122) (145)	(5,12,9) (9)	(5,6,8) (6)	(23,21,34) (26)
Code #4	0.00032 mg/plate	no	(22,12,12) (15)	(100,85,114) (100)	(8,18,16) (14)	(5,4,cont) (4)	(12,7,8) (9)
		yes	(27,26,29) (27)	(130,96,126) (117)	(8,7,6) (6)	(9,2,5) (5)	(17,30,15) (21)

Study Number: 81014 Date: 19 June 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 5D

NUMBER OF REVERTANTS/PLATE

Compd.	Amount of Compd. Added	S-9 Added	Strain Number 98	100	1535	1537	1538
Code #96	1 mg/plate	no	(19,17,12) (16)	(137,95,95) (109)	(15,17,15) (16)	(4,5,7) (5)	(5,9,5) (6)
		yes	(35,20,24) (26)	(121,145,105) (124)	(9,12,11) (11)	(8,6,7) (6)	(33,20,11) (21)
Code #96	0.2 mg/plate	no	(18,13,14) (15)	(85,96,77) (86)	(14,9,11) (11)	(4,8,5) (6)	(6,4,13) (8)
		yes	(35,27,27) (30)	(124,130,118) (124)	(5,11,11) (9)	(4,6,7) (6)	(16,9,15) (13)
Code #96	0.04 mg/plate	no	(12,15,27) (18)	(68,98,104) (90)	(18,15,18) (17)	(6,6,5) (6)	(3,12,13) (11)
		yes	(35,35,34) (35)	(146,99,120) (122)	(12,8,8) (9)	(7,6,7) (7)	(18,9,20) (16)

-continued

Study Number: 81014 Date: 19 Jun 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 5D , concluded

NUMBER OF REVERTANTS/PLATE

Compd.	Amount of Compd. Added	S-9 Added	Strain Number 98	100	1535	1537	1538
Code #96	0.008 mg/plate	no	(13,18,11) (14)	(96,95,10) (67)	(13,15,14) (14)	(5,10,4) (6)	(17,12,9) (13)
		yes	(25,29,24) (26)	(113,113,117) (114)	(11,8,11) (10)	(4,3,2) (3)	(23,26,18) (22)
Code #96	0.0016 mg/plate	no	(12,17,14) (14)	(85,93,79) (86)	(18,9,18) (15)	(3,4,6) (4)	(10,10,17) (12)
		yes	(26,29,28) (28)	(118,124,110) (117)	(6,10,10) (9)	(4,7,7) (6)	(17,21,23) (20)
Code #96	0.00032 mg/plate	no	(13,19,19) (17)	(90,92,108) (97)	(17,12,9) (13)	(6,7,9) (7)	(17,12,13) (14)
		yes	(26,30,26) (27)	(117,146,108) (124)	(11,7,6) (8)	(4,7,6) (6)	(26,23,20) (23)

Study Number: 81014 Date: 19 Jun 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 6A

MUTAGENIC ACTIVITY RATIO

Substance Assayed: Code #86 Dissolved in: DMSO

Study Number: 81014 Date: 23 July 1981 By: Sauers

Concentration	Strain	MUTAR (act)	MUTAR	Concentration	Strain	MUTAR (act)	MUTAR
1.0 mg/plate	TA 98	*	*	0.008 mg/pl.	TA 1535	*	*
0.2 mg/plate	TA 98	*	*	0.0016 mg/pl.	TA 1535	0.45	*
0.04 mg/plate	TA 98	0.08	*	0.00032 mg/pl.	TA 1535	0.18	*
0.008 mg/plate	TA 98	*	*				
0.0016 mg/pl.	TA 98	*	*	1.0 mg/plate	TA 1537	*	*
0.00032 mg/pl.	TA 98	*	*	0.2 mg/plate	TA 1537	*	*
				0.04 mg/plate	TA 1537	*	*
1.0 mg/plate	TA 100	*	0.01	0.008 mg/pl.	TA 1537	*	0.15
0.2 mg/plate	TA 100	*	*	0.0016 mg/pl.	TA 1537	0.46	0.31
0.04 mg/plate	TA 100	0.06	*	0.00032 mg/pl.	TA 1537	*	*
0.008 mg/plate	TA 100	0.02	0.02				
0.0016 mg/pl.	TA 100	0.08	0.08	1.0 mg/plate	TA 1538	*	*
0.00032 mg/pl.	TA 100	*	0.12	0.2 mg/plate	TA 1538	0.53	*
				0.04 mg/plat	TA 1538	0.59	*
1.0 mg/plate	TA 1535	*	*	0.008 mg/plate	TA 1538	0.43	*
0.2 mg/plate	TA 1535	*	*	0.0016 mg/pl.	TA 1538	0.16	*
0.04 mg/plate	TA 1535	*	*	0.00032 mg/pl.	TA 1538	0.16	*

(act): S-9 fraction was added

* : calculated value resulted in a negative MUTAR or zero MUTAR

TABLE 6B

MUTAGENIC ACTIVITY RATIO

Substance Assayed: Code # 44 Dissolved in: DMSO

Study Number: 81014 Date: 23 July 1981 By: Sauers

Concentration	Strain	MUTAR (act)	MUTAR	Concentration	Strain	MUTAR (act)	MUTAR
1.0 mg/plate	TA 98	*	*	0.008 mg/plate	TA 1535	0.18	0.13
0.2 mg/plate	TA 98	*	*	0.0016 mg/pl.	TA 1535	0.09	*
0.04 mg/plate	TA 98	*	*	0.00032 mg/pl.	TA 1535	0.45	*
0.008 mg/plate	TA 98	*	*				
0.0016 mg/pl.	TA 98	*	*	1.0 mg/plate	TA 1537	*	*
0.00032 mg/pl.	TA 98	*	*	0.2 mg/plate	TA 1537	*	*
				0.04 mg/plate	TA 1537	*	*
1.0 mg/plate	TA 100	*	*	0.008 mg/plate	TA 1537	*	*
0.2 mg/plate	TA 100	0.01	*	0.0016 mg/pl.	TA 1537	*	*
0.04 mg/plate	TA 100	*	*	0.00032 mg/pl.	TA 1537	*	*
0.008 mg/plate	TA 100	0.04	*				
0.0016 mg/pl.	TA 100	*	*	1.0 mg/plate	TA 1538	*	*
0.00032 mg/pl.	TA 100	*	0.06	0.2 mg/plate	TA 1538	0.16	*
				0.04 mg/plate	TA 1538	0.05	*
1.0 mg/plate	TA 1535	*	*	0.008 mg/plate	TA 1538	0.05	*
0.2 mg/plate	TA 1535	*	*	0.0016 mg/plate	TA 1538	0.21	*
0.04 mg/plate	TA 1535	0.09	0.13	0.00032 mg/pl.	TA 1538	*	*

(act): S-9 fraction was added

* : calculated value resulted in a negative MUTAR or zero MUTAR

TABLE 6C

MUTAGENIC ACTIVITY RATIO

Substance Assayed: Code #4 Dissolved in: DMSO

Study Number: 81014 Date: 23 July 1981 By: Sauers

Concentration	Strain	MUTAR (act)	MUTAR	Concentration	Strain	MUTAR (act)	MUTAR
1.0 mg/plate	TA 98	*	*	0.008 mg/plate	TA 1535	*	0.32
0.2 mg/plate	TA 98	*	*	0.0016 mg/pl.	TA 1535	*	*
0.04 mg/plate	TA 98	*	*	0.00032 mg/pl.	TA 1535	*	*
0.008 mg/plate	TA 98	*	*				
0.0016 mg/pl.	TA 98	0.24	*	1.0 mg/plate	TA 1537	*	*
0.00032 mg/pl.	TA 98	*	*	0.2 mg/plate	TA 1537	*	*
				0.04 mg/plate	TA 1537	*	*
1.0 mg/plate	TA 100	0.25	0.12	0.008 mg/plate	TA 1537	*	0.15
0.2 mg/plate	TA 100	*	*	0.0016 mg/pl.	TA 1537	*	*
0.04 mg/plate	TA 100	0.06	*	0.00032 mg/pl.	TA 1537	*	*
0.008 mg/plate	TA 100	0.23	*				
0.0016 mg/pl.	TA 100	0.29	0.05	1.0 mg/plate	TA 1538	*	*
0.00032 mg/pl.	TA 100	0.03	0.06	0.2 mg/plate	TA 1538	*	*
				0.04 mg/plate	TA 1538	*	*
1.0 mg/plate	TA 1535	*	*	0.008 mg/plate	TA 1538	0.37	0.42
0.2 mg/plate	TA 1535	0.18	*	0.0016 mg/pl.	TA 1538	0.37	*
0.04 mg/plate	TA 1535	0.09	*	0.00032 mg/pl.	TA 1538	0.11	*

(act): S-9 fraction was added

* : calculated value resulted in a negative MUTAR or zero MUTAR

TABLE 6D

MUTAGENIC ACTIVITY RATIO

Substance Assayed: Code #96 Dissolved in: DMSO

Study Number: 81014 Date: 23 July 1981 By: Sauers

Concentration	Strain	MUTAR (act)	MUTAR	Concentration	Strain	MUTAR (act)	MUTAR
1.0 mg/plate	TA 98	*	*	0.008 mg/plate	TA 1535	*	*
0.2 mg/plate	TA 98	*	*	0.0016 mg/pl.	TA 1535	*	*
0.04 mg/plate	TA 98	0.2	*	0.00032 mg/pl.	TA 1535	*	*
0.008 mg/plate	TA 98	*	*				
0.0016 mg/pl.	TA 98	*	*	1.0 mg/plate	TA 1537	*	*
0.00032 mg/pl.	TA 98	*	*	0.2 mg/plate	TA 1537	*	*
				0.04 mg/plate	TA 1537	*	*
1.0 mg/plate	TA 100	0.09	0.16	0.008 mg/plate	TA 1537	*	*
0.2 mg/plate	TA 100	0.09	*	0.0016 mg/pl.	TA 1537	*	*
0.04 mg/plate	TA 100	0.07	*	0.00032 mg/pl.	TA 1537	*	*
0.008 mg/plate	TA 100	*	*				
0.0016 mg/pl.	TA 100	0.03	*	1.0 mg/plate	TA 1538	0.11	*
0.00032 mg/pl.	TA 100	0.09	0.03	0.2 mg/plate	TA 1538	*	*
				0.04 mg/plate	TA 1538	*	*
1.0 mg/plate	TA 1535	0.09	*	0.008 mg/plate	TA 1538	0.16	*
0.2 mg/plate	TA 1535	*	*	0.0016 mg/pl.	TA 1538	0.05	*
0.04 mg/plate	TA 1535	*	*	0.00032 mg/pl.	TA 1538	0.21	*

(act): S-9 fraction was added

* : calculated value resulted in a negative MUTAR or zero MUTAR

OFFICIAL DISTRIBUTION LIST

Commander
US Army Medical Research and Development Command
ATTN: SGRD-SI/ Mrs. Madigan
Fort Detrick, Frederick MD 21701

Defense Technical Information Center
ATTN: DTIC-DDA (12 copies)
Cameron Station
Alexandria VA 22314

Director of Defense Research and Engineering
ATTN: Assistant Director, Environmental and Life Sciences
Washington DC 20301

The Surgeon General
ATTN: DASG-TLO
Washington DC 20314

HQ DA (DASG-ZXA)
WASH DC 20310

Superintendent
Academy of Health Sciences
ATTN: AHS-COM
Fort Sam Houston TX 78234

Assistant Dean
Institute and Research Support
Uniformed Services University of Health Sciences
6917 Arlington Road
Bethesda MD 20014

Commander
US Army Environmental Hygiene Agency
Aberdeen Proving Ground MD 21070

US Army Research Office
ATTN: Chemical and Biological Sciences Division
P.O. Box 1221
Research Triangle Park NC 27709

Biological Sciences Division
Office of Naval Research
Arlington VA 22217

Director of Life Sciences
USAF Office of Scientific Research (AFSC)
Bolling AFB
Washington DC 20332

Director
Walter Reed Army Institute of Research
Washington DC 20012

Commander
US Army Medical Research Institute of Infectious Diseases
Fort Detrick, Frederick MD 21701

Commander
US Army Research Institute of Environmental Medicine
Natick MA 01760

Commander
US Army Institute of Surgical Research
Brooke Army Medical Center
Fort Sam Houston TX 78234

Commander
US Army Institute of Dental Research
Washington DC 20012

Commander
US Army Medical Bioengineering Research and Development Laboratory
Fort Detrick, Frederick MD 21701

Commander
US Army Aeromedical Research Laboratory
Fort Rucker AL 36362

Commander
US Army Biomedical Laboratory
Aberdeen Proving Ground
Edgewood Arsenal MD 21010

Commander
Naval Medical Research Institute
National Naval Medical Center
Bethesda MD 20014

Commander
USAF School of Aerospace Medicine
Aerospace Medical Division
Brooks Air Force Base TX 78235


LMED
8